fda compounding semaglutide crackdown news today The is drawing a harder line on compounded weight loss drug marketing. In the May–June 2026 issue of Dispense Times, this article breaks down key violations cited in recent FDA enforcement The Food and Drug Administration's

The primary function of GLP-1 is to stimulate the release of insulin from the pancreas, which lowers blood sugar levels, and to reduce the production of glucose in the liver

New 2025 research explains why both happen: this drug activates CB1 and CB2 receptors

Previous research has demonstrated the presence of GLP-1 receptors in murine hair follicles, although their precise role in the hair growth cycle remains undefined

Retatrutide builds upon this concept by targeting GLP-1, GIP, and glucagon receptors simultaneously

Usually, it occurs after eating certain foods or drinking carbonated drinks

The compound belongs to an advanced therapeutic category known as triple agonists, which distinguishes it from earlier weight management medications